Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07207148 · ClinicalTrials.gov registry record
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
A clinical trial of Multiple Sclerosis, sponsored by Northwestern University.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07207148 is a study of Multiple Sclerosis that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 100 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07207148, a study of Multiple Sclerosis, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest. For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hole peg test, and SDMT score.
Conditions Studied
Interventions
- DRUG Ocrelizumab (US)
- DRUG GLP-1
Study Locations (1)
Illinois
- Northwestern Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11-15 |
| Est. Completion | 2028-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07207148
The ClinicalTrials.gov registry entry for NCT07207148 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (83% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Ocrelizumab (US) is the first listed.
NCT07207148 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT07207148 about?
NCT07207148 is a clinical study titled "People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists". The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of int...
What is the current status of trial NCT07207148?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-11-15. Estimated completion is 2028-08-31.
What conditions does trial NCT07207148 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT07207148?
The interventions under investigation include: Ocrelizumab (US) (DRUG), GLP-1 (DRUG).
Who is sponsoring clinical trial NCT07207148?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07207148 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.